4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This licence authorises the supply of GMP-grade ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. 4basebio UK Societas ( (GB:4BB)) has provided an announcement. 4basebio has received Good Manufacturing ...

PLC (LON:4BB – Get Free Report) insider Heikki Lanckriet purchased 2,400 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was acquired at an average ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cambridge, UK, 7 March 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that, pursuant ...

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA ...

Assess the 4BASEBIO UK SOCIETAS Income Statement (earnings report), showing the company's financial performance from operating and non operating activities such as revenue, expenses and income. Check ...

4basebio PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

4basebio PLC (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has ...